Overview
- The company started shipping and fulfilling first customer orders for Arbli, a 10 mg/mL losartan potassium oral suspension.
- It is the first FDA-approved, ready-to-use liquid formulation of losartan for patients aged six and older who need a non-solid dosage form.
- The product requires no compounding, features reduced dosing volume, and has a long-term shelf life at room temperature.
- PBM-led and multiple GPO agreements expand formulary and institutional access across hospitals, clinics, long-term care facilities, specialty pharmacies, and ambulatory centers, representing an estimated 20% of the U.S. institutional market.
- Scienture reported targeted outreach to healthcare professionals and a roughly 140% share price jump to about $1.38 during Thursday trading, as IQVIA cites a $256 million U.S. losartan market with about 71 million annual prescriptions.